Compliance audit

BRAND

Example Peptide Clinic (fictional sample)

REFERENCE

PK-CA-20261121-021503

Generated 2026-11-21

PERIOD

2026-10-01 to 2026-10-31

A FICTIONAL SAMPLE

Every brand, order, lot, certificate and person in this document is invented, to show what an audit holds. The rules quoted are real, read from each source by Provkeep, verbatim.

WHAT THIS IS

Every live order Example Peptide Clinic (fictional sample) sent to Provkeep that was placed from 2026-10-01 to 2026-10-31, the rule each was checked against on its own date, what the brand did afterwards, and what its records hold. Generated on schedule, with no person choosing what went in.

HOW TO READ IT

It reports what happened and which published rule applied, in the rule's own words with its source. It does not say whether anything was lawful, and it makes no finding about the brand: that judgement is for the reader. Where a section found nothing, it says so.

SUMMARY

Each count is in full in the section named beside it.

WHAT	COUNT	SECTION
Orders checked in the period	9	1
Order lines checked	11	1
Lines to a state whose rule restricts the product	1	1
Lines to a state where conditions apply	0	1
Orders held, or asked to be held	1	2
Lines where a rule turned on something the order did not show	0	3
Lines with no lot tied	1	4
Lots shipped with no confirmed certificate	1	4
Lines shipped from a lot past its expiry date	0	4
Lots shipped whose certificate reports a failed result	0	4
Orders with no consent record	1	4
Rules that appeared or ended for these products	0	5
Federal positions in force	1	6

1 Orders checked

11 order lines on 9 orders were checked in the period. 1 repeated send of an order already counted is not counted again.

WHAT THE RULES SAID	LINES
Restricted	1
Federal position applies	4
No state restriction found	6

To a state where the rule restricts the product: 1

2026-10-06. Order EX-1004, line 1: BPC-157 to Ohio. Since: held on 2026-10-06, hold released on 2026-10-07, cancelled on 2026-10-07.

> "Additionally, peptides such as BPC-157 and other bulk drug substances in category 2 and 3 (see FDA guidance) cannot be compounded because it violates federal and state law."
>
> OH pharmacy board: Ten Common Prescriber Clinic and Medical Spa Violations, read 2026-11-20. https://www.pharmacy.ohio.gov/documents/pubs/special/ivtherapy/ten%20common%20prescriber%20clinic%20and%20medical%20spa%20violations.pdf

To a state where conditions apply: 0

None in the period.

2 What the brand did

Holding orders marked Restricted was switched on for this account when this audit was made.

Order EX-1004, BPC-157, placed 2026-10-06

Hold asked for	Yes, by Provkeep
Held	2026-10-06, Provkeep plugin, as set in Provkeep
Released	2026-10-07 by A. Rivera, operations (fictional)
Note	Cancelled and refunded. We do not ship BPC-157 to Ohio.
Then	cancelled on 2026-10-07

3 Conditions a rule turned on that the order did not show

A state rule can depend on what the order was for, or on how the patient was seen, including in person. These orders did not say, so the rule could not be matched to them either way.

None in the period.

4 Gaps in the record

Lines with no lot tied: 1

ORDER	PRODUCT	PLACED
EX-1009	NAD+	2026-10-21

Lots shipped with no confirmed certificate: 1

LOT	PRODUCT	LINES
EX-NAD-0921	NAD+	2

Lines shipped from a lot past its expiry date: 0

None in the period.

Lots shipped whose confirmed certificate reports a failed result: 0

None in the period.

Orders with no consent record: 1

ORDER	PLACED
EX-1009	2026-10-21

5 Rules that changed during the period

A rule that appeared, ended or was withdrawn in the period, for a product the brand sold in it. For a new rule, the orders it would have reached, placed before it appeared, are listed.

No rule for these products appeared or ended in the period.

6 Federal positions in force during the period

BPC-157: FDA: certain bulk drug substances that may present significant safety risks

> "Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization."
>
> In force.
> https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

Generated by Provkeep from this account's own records and the published sources cited. Every quotation is verbatim. Check this document's seal with its Verify link.